Across Europe*, by 30 June 2016, the pharmaceutical industry will disclose payments made to health professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis for collaboration in the future. Industry is being proactive, based on its commitment to this relationship. Collaboration between industry and health professionals benefits patients. It is a relationship that has delivered numerous innovative medicines and changed the way many diseases impact on our lives. Industry and health professionals collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway. Society has increasingly high expectations for transparency, none more so than in healthcare. We want to ensure we meet those expectations going forward. We are keen to work with our partners, the HCP community and professional organisations to ensure this vital relationship is understood by patients, the media and other stakeholders.
EFPIA member associations have been working to transpose the EFPIA Disclosure Code in to national Codes of Practice and discuss the changes with health professional colleagues. By clicking on a country in the interactive map below, you can access the resources on disclosure of payments to healthcare professionals created by EFPIA Member Associations.
* “Europe”, as used in th EFPIA Disclosure Code, refers to, collectively, those countries for which there is an EFPIA Member Association.Those countries currently include the following 33 countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, Norway, Poland, Portugal, Romania,Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.